IBEX Wealth Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-1,500
Closed -$21.1K 88
2024
Q2
$21.1K Buy
+1,500
New +$24.4K ﹤0.01% 194
2021
Q4
Sell
-1,500
Closed -$15K 209
2021
Q3
$15K Buy
+1,500
New +$11.8K ﹤0.01% 334
2019
Q3
Sell
-1,500
Closed -$4K 108
2019
Q2
$4K Buy
+1,500
New +$2.58K ﹤0.01% 359

Other funds holding AVDL

IBEX Wealth Advisors's AVDL Position: Q3 2024 in Review

IBEX Wealth Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q3 2024, closing a stake of 1,500 shares — an estimated $21.1K sold.

IBEX Wealth Advisors first reported a position in AVDL in Q2 2019 and held it in 3 quarters. The position peaked at $21.1K in Q2 2024. 176 funds tracked by Wall St. Rank hold AVDL as of Q3 2024.

  • IBEX Wealth Advisors reported no remaining Avadel Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • IBEX Wealth Advisors sold 1,500 Avadel Pharmaceuticals shares in Q3 2024, an estimated $21.1K.
  • IBEX Wealth Advisors first reported a position in Avadel Pharmaceuticals in Q2 2019 and held it in 3 quarters.
  • IBEX Wealth Advisors's Avadel Pharmaceuticals position peaked at $21.1K in Q2 2024.
  • 176 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2024.

Based on IBEX Wealth Advisors's 13F filing for Q3 2024, filed 4 Nov 2024.